Allspring Global Investments’s Karyopharm Therapeutics KPTI Stock Holding History

Allspring Global Investments’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-998	Closed	-$20.1K	–	2491
2023 Q3	$20.1K	Buy	+998	New	+$22.4K	﹤0.01%	2510
2023 Q2	–	Sell	-1,640	Closed	-$95.7K	–	2763
2023 Q1	$95.7K	Sell	1,640 -133	-8%	-$6.57K	﹤0.01%	2067
2022 Q4	$90.4K	Sell	1,773 -662	-27%	-$45.9K	﹤0.01%	2110
2022 Q3	$199K	Buy	2,435 +761	+45%	+$56.8K	﹤0.01%	1817
2022 Q2	$113K	Sell	1,674 -1,574	-48%	-$144K	﹤0.01%	2016
2022 Q1	$359K	Buy	3,248 +678	+26%	+$84.5K	﹤0.01%	2370
2021 Q4	$247K	Buy	+2,570	New	+$256K	﹤0.01%	2575

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments's KPTI Position: Q4 2023 in Review

Allspring Global Investments sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 998 shares — an estimated $20.1K sold.

Allspring Global Investments first reported a position in KPTI in Q4 2021 and held it in 7 quarters. The position peaked at $359K in Q1 2022. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

Allspring Global Investments reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
Allspring Global Investments sold 998 Karyopharm Therapeutics shares in Q4 2023, an estimated $20.1K.
Allspring Global Investments first reported a position in Karyopharm Therapeutics in Q4 2021 and held it in 7 quarters.
Allspring Global Investments's Karyopharm Therapeutics position peaked at $359K in Q1 2022.
117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.